CASIF
What one share of Casi Pharmaceuticals holds
Pharmaceutical Preparations
The Company has historically built and operated a fully integrated biopharmaceutical organization dedicated to the development and commercialization of innovative therapeutics, with a primary focus on the hematology/oncology field and the China market.
Casi Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Sales | $1.12 |
|---|---|
| Profit | −$2.59 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.12 |
| Cash and investments | $0.27 |
| Book value | −$1.81 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $1.37 | −$4.37 | $0.14 | −$2.48 | — | $7.38 |
| 2021 | $2.22 | −$2.69 | $0.66 | −$2.63 | — | $6.04 |
| 2022 | $3.16 | −$3.01 | $0.41 | −$1.96 | — | $3.31 |
| 2023 | $2.54 | −$2.02 | $0.02 | −$1.51 | — | $1.81 |
| 2024 | $1.86 | −$2.56 | $0.01 | −$1.92 | — | $0.12 |
| 2025 | $1.12 | −$2.59 | $0.00 | −$1.12 | — | −$1.81 |